You are here: Industry Insights > Ultomiris

News List

CHMP recommends expanded use for Alexion’s PNH therapy Ultomiris pharmatimes
July 27, 2021
AstraZeneca’s (AZ) Ultomiris has received a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) to expand its use to include children and adults with ...
AZ scores final clearance for Alexion acquisition in the UK pharmatimes
July 15, 2021
AstraZeneca (AZ) is expecting its acquisition of Alexion Pharmaceuticals to close on 21 July after receiving final clearance from the UK Competition and Markets Authority (CMA).
FDA approves therapy for pediatric patients with serious rare blood disease fda.gov
June 09, 2021
FDA has approved Ultomiris (ravulizumab-cwvz) injection to treat patients aged one month and older with paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening blood disease.
UK patients with rare blood disorders receive new treatment option europeanpharmaceuticalreview
May 21, 2021
NICE has recommended that Ultomiris (ravulizumab) be available on the NHS for patients with paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome.
NHS patients with rare blood disorders gain access to Ultomiris pharmatimes
May 21, 2021
NHS patients with paroxysmal nocturnal haemoglobinuria (PNH) or atypical haemolytic uraemic syndrome (aHUS) are to get access to treatment with Alexion's Ultomiris (ravulizumab) following a green light from cost regulators.
SMC endorses Alexion’s Ultomiris pharmatimes
May 12, 2021
The Scottish Medicines Consortium (SMC) has accepted a treatment for an ultra-rare disease that can cause progressive injury to vital organs via damage to the walls of blood vessels and blood clots in its May decisions.
NICE recommends Alexion’s PNH treatment Ultomiris pharmatimes
April 19, 2021
The National Institute for Health and Care Excellence (NICE) has recommended Alexion’s C5 complement inhibitor Ultomiris for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).
SMC approves funding for four new medicines on the NHS pharmatimes
February 09, 2021
In its February 2021 meeting, the Scottish Medicines Consortium (SMC) has accepted four new medicines for use by the NHS in Scotland.
FDA Approves New Treatment for Paroxysmal Nocturnal Hemoglobinuria americanpharmaceuticalreview
December 27, 2018
The U.S. Food and Drug Administration (FDA) approved Ultomiris (ravulizumab) injection for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease.....
FDA Approves Ultomiris (ravulizumab-cwvz) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) drugs
December 26, 2018
Alexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvz).....